Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | IKBKB | O14920 | 8/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CCNH | P51946 | 1/20 | 0.36 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638310 | 0.86 | KDM1A (0.37) | KCNH2IKBKBAURKATTKAURKB | |
| SCHEMBL4493372 | 0.82 | KCNH2 (0.64) | KCNH2IKBKBAURKATTKAURKB | |
| SCHEMBL3471613 | 0.79 | IKBKB (0.49) | KCNH2IKBKBAURKATTKAURKB | |
| SCHEMBL4489709 | 0.78 | IKBKB (0.48) | KCNH2IKBKBAURKATTKAURKB | |
| SCHEMBL3470852 | 0.78 | IKBKB (0.48) | KCNH2IKBKBAURKATTKAURKB | |
| SCHEMBL4488019 | 0.78 | MEN1 (0.48) | KCNH2IKBKBAURKATTKAURKB | |
| SCHEMBL3473827 | 0.77 | IKBKB (0.46) | KCNH2IKBKBAURKATTKAURKB | |
| SCHEMBL3472520 | 0.77 | IKBKB (0.46) | KCNH2IKBKBAURKATTKAURKB | |
| SCHEMBL3472513 | 0.76 | IKBKB (0.46) | KCNH2IKBKBAURKATTKAURKB | |
| SCHEMBL3470408 | 0.75 | KCNH2 (0.66) | KCNH2IKBKBKDM1ACDK2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | claimed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | claimed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | claimed |
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2010134939-A2 | MAMMALIAN GENES INVOLVED IN INFECTION | Zirus, Inc. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | KCNH2 3073/4885IKBKB 2/4885AURKA 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.